Reversing Disease Signals

Episode Summary

Executive Summary: Ben Ziskin, CEO of Immuneering, explains how the company evolved from bioinformatics services into a drug-development platform built around “disease-canceling technology.” Using human gene-expression data, the platform aims to identify targets and compounds that counter disease signatures, with a lead program in cancer cachexia and several preclinical assets. Ziskin argues this approach improves speed, cost, and relevance versus traditional discovery methods.

Main Topics: Immuneering’s evolution from services to drug discovery (Priority: 5/5): Ziskin describes the company’s origins in advanced bioinformatics services and how that work informed a shift into proprietary drug development after years of analyzing pharma datasets and mechanisms of action. Disease-canceling technology as the core platform (Priority: 5/5): The company’s platform uses gene-expression signatures from human disease data to identify targets and compounds intended to reverse disease-associated signals, rather than relying on single-target, trial-and-error discovery. Why traditional discovery fails (Priority: 5/5): Ziskin argues that conventional approaches over-rely on cell lines, animal models, serendipity, and experimental screening, which can miss complex human disease biology and waste time and capital. Cancer cachexia as a lead indication (Priority: 4/5): Immuneering’s disclosed lead program targets cancer cachexia, a severe muscle-wasting condition in late-stage cancer that is under-served by current therapies and difficult to model with conventional methods. Capital efficiency and pipeline generation (Priority: 4/5): The platform is presented as faster and more capital-efficient than traditional discovery, enabling a steadier stream of new assets and a hybrid model of either advancing programs internally or partnering them after proof of concept. Biotech business model and financing (Priority: 3/5): Ziskin explains that the services business funded early R&D, allowing Immuneering to raise a Series A only after 11 years, and that the company’s economics may support earlier licensing transactions.

Key Arguments: Immuneering’s service work built deep expertise in rigorous bioinformatics, which became the foundation for its proprietary drug-discovery platform. Successful drugs often act less like precise “bullets” and more like signal inducers that reshape gene-expression programs, informing the company’s anti-noise metaphor. Starting from human patient data rather than model systems may improve the likelihood of discovering therapies that translate clinically. The platform can computationally perform target identification and virtual screening, reducing dependence on slow, expensive experimental trial-and-error. Disease-canceling technology is designed to address complex disease states, such as cachexia, that traditional target-centric discovery is poorly suited to treat. Immuneering says its internal pipeline has been about twice as fast and three times as capital efficient as benchmarks from inception to in vivo proof of concept. The company’s strong services revenue helped finance early discovery work and supported a longer runway before institutional fundraising. A steady output of programs creates flexibility: Immuneering can either develop assets itself or license them earlier depending on program-specific economics.

Data Points: Service revenue growth: 103% compound annual growth rate - Reported for the first seven years of Immuneering’s services business Company age at Series A: 11 years - Ziskin says the company raised a Series A after being in business for 11 years Platform efficiency vs. benchmarks: About 2x faster - Internal pipeline performance from inception to in vivo proof of concept Capital efficiency vs. benchmarks: About 3x more capital efficient - Internal pipeline performance from inception to in vivo proof of concept Lead program indication: Cancer cachexia - Lead disclosed program targeting muscle wasting in late-stage cancer patients Disease burden: About one-third of all cancer deaths - Ziskin says cachexia is the final cause of roughly a third of cancer deaths Computational screening scale: Tens of millions of compounds - Virtual chemistry step screens large compound libraries for predicted binding affinity Pipeline size: Six programs - Ziskin references the company having six programs in its pipeline Speaker affiliation: Co-founder and CEO of Immuneering - Ben Ziskin’s role during the interview

Pivotal Quotes: "“we came to view successful drugs more as signal inducers than bullets”" — Ben Ziskin: Explaining the conceptual insight that led to Immuneering’s platform design "“we call it disease-canceling technology, by the way, for hopefully obvious reasons”" — Ben Ziskin: Describing the company’s proprietary technology and the noise-canceling headset metaphor "“we're about twice as fast and about three times as capital efficient as sort of a traditional benchmark”" — Ben Ziskin: Discussing internal performance of the discovery platform from inception to in vivo proof of concept

Implications: If validated clinically, Immuneering’s approach could shorten discovery timelines, reduce R&D waste, and improve translation from human biology to medicines—especially for complex diseases with few good treatment options.